- |||||||||| simvastatin / Generic mfg.
Trial termination: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins (clinicaltrials.gov) - Mar 12, 2024 P1, N=12, Terminated, Phase classification: P1/2 --> P1 Completed --> Terminated; Research was completed before January 18, 2017, & does not meet the Applicable Clinical Trial requirement to register & report results per the guidance provided in "Clinical Trials Registration & Results Information Submission" dated 09/21/2016.
- |||||||||| dexamethasone / Generic mfg., bendamustine / Generic mfg., pomalidomide / Generic mfg.
Trial completion date: Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma (clinicaltrials.gov) - Feb 20, 2024 P1/2, N=56, Active, not recruiting, Completed --> Terminated; Research was completed before January 18, 2017, & does not meet the Applicable Clinical Trial requirement to register & report results per the guidance provided in "Clinical Trials Registration & Results Information Submission" dated 09/21/2016. Trial completion date: Jan 2023 --> Jan 2025
- |||||||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Phase classification, Combination therapy: Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov) - Jan 24, 2024 P1, N=3, Terminated, Trial completion date: Jan 2023 --> Jan 2025 Phase classification: P1/2 --> P1
- |||||||||| lenalidomide / Generic mfg.
Trial completion, Trial completion date: IFM2005-02: Maintenance Therapy Using Lenalidomide in Myeloma (clinicaltrials.gov) - Apr 26, 2019 P3, N=614, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Sep 2018
- |||||||||| Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Apr 20, 2019 P2, N=21, Completed, Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Sep 2018 Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg.
Trial completion: Bortezomib Consolidation Trial (clinicaltrials.gov) - Apr 20, 2019 P2, N=40, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: IFM/DFCI2009: Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (clinicaltrials.gov) - Apr 20, 2019 P3, N=700, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018
- |||||||||| bortezomib / Generic mfg.
Trial completion: Autophagy Induction After Bortezomib for Myeloma (clinicaltrials.gov) - Apr 20, 2019 P1, N=11, Completed, Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Nov 2018 | Trial primary completion date: Sep 2018 --> Nov 2018 Active, not recruiting --> Completed
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Apr 2, 2019
P=N/A, N=23, Terminated, Active, not recruiting --> Completed | N=26 --> 18 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
- |||||||||| Trial completion, HEOR: PSY_HaEMOPEQ: Effectiveness of Psychological Interventions in Haemophilia (clinicaltrials.gov) - Mar 26, 2019
P=N/A, N=20, Completed, N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. Active, not recruiting --> Completed
- |||||||||| staphylococcal protein A (PRTX-100) / Protalex
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) - Mar 25, 2019 P1b, N=15, Terminated, Active, not recruiting --> Completed N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit.
- |||||||||| Promacta (eltrombopag) / Novartis
Trial completion date, Trial termination, Trial primary completion date: Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (clinicaltrials.gov) - Mar 18, 2019 P2, N=24, Terminated, N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit. Trial completion date: Jun 2020 --> Jun 2017 | Active, not recruiting --> Terminated | Trial primary completion date: May 2019 --> May 2017; retirement of PI
- |||||||||| bortezomib / Generic mfg.
Trial completion, Enrollment change: Evaluation of Cardiotoxic Effects of Bortezomib (clinicaltrials.gov) - Mar 14, 2019 P=N/A, N=11, Completed, Active, not recruiting --> Terminated; lack of recruitment Not yet recruiting --> Completed | N=20 --> 11
- |||||||||| Campath (alemtuzumab) / Sanofi, Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System (clinicaltrials.gov) - Mar 5, 2019 P2, N=92, Completed, Completed --> Terminated; The study was terminated by the Sponsor for administrative reasons and not due to any safety concerns. Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Feb 20, 2019
P=N/A, N=19, Completed, N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017
- |||||||||| Biomarker, Enrollment change, Trial withdrawal: The Role of Microparticles as a Biomarker (clinicaltrials.gov) - Feb 19, 2019
P=N/A, N=0, Withdrawn, Active, not recruiting --> Completed | Trial completion date: Nov 2019 --> Aug 2017 N=200 --> 0 | Enrolling by invitation --> Withdrawn
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Individualizing Hemophilia Prophylaxis Using Thromboelastography (clinicaltrials.gov) - Feb 18, 2019
P=N/A, N=18, Completed, N=200 --> 0 | Enrolling by invitation --> Withdrawn Recruiting --> Completed | N=60 --> 18 | Trial completion date: Dec 2018 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2017
- |||||||||| Enrollment closed: HeL-Fascial: Fascial Therapy in Elbow Hemophilic Arthropathy (clinicaltrials.gov) - Feb 6, 2019
P=N/A, N=60, Active, not recruiting, Recruiting --> Completed | N=60 --> 18 | Trial completion date: Dec 2018 --> Dec 2017 | Trial primary completion date: Dec 2018 --> Dec 2017 Recruiting --> Active, not recruiting
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: MRA With Feraheme in HHT (clinicaltrials.gov) - Jan 25, 2019
P1, N=10, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2016 --> Jun 2018 | Trial primary completion date: Dec 2016 --> Oct 2017 Recruiting --> Completed | Trial completion date: Nov 2017 --> Nov 2018 | Trial primary completion date: Nov 2017 --> Nov 2018
- |||||||||| Enrollment change, Trial withdrawal: KAPPA: Key Aspects of Medical Practice in Patients With Haemophilia A (clinicaltrials.gov) - Dec 22, 2018
P=N/A, N=0, Withdrawn, Active, not recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2018 | Trial primary completion date: Dec 2018 --> Apr 2018 N=1000 --> 0 | Enrolling by invitation --> Withdrawn
- |||||||||| Biomarker, Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Correlative Biomarker Study in Patients With Myeloproliferative Disorders (clinicaltrials.gov) - Dec 13, 2018
P=N/A, N=592, Completed, Trial completion date: Jun 2014 --> Oct 2018 Recruiting --> Completed | N=860 --> 592 | Trial completion date: Jun 2019 --> Jul 2018 | Trial primary completion date: Jun 2019 --> Jul 2018
- |||||||||| Kinaction (masitinib) / AB Science
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy: A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2018 P3, N=147, Terminated, N=25 --> 8 | Recruiting --> Terminated; low enrollment N=300 --> 147 | Trial completion date: Dec 2014 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Apr 2013 --> Jun 2018; Sponsor decision based on portfolio prioritization
|